Eaton Vance Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $143M | Sell |
|
|||||
|
2022
Q2 | $143M | Buy |
|
|||||
|
2022
Q1 | $137M | Sell |
|
|||||
|
2021
Q4 | $157M | Sell |
|
|||||
|
2021
Q3 | $181M | Buy |
|
|||||
|
2021
Q2 | $120M | Buy |
|
|||||
|
2021
Q1 | $79.4M | Buy |
|
|||||
|
2020
Q4 | $50.7M | Buy |
|
|||||
|
2020
Q3 | $12.4M | Hold |
|
|||||
|
2020
Q2 | $15.7M | Hold |
|
|||||
|
2020
Q1 | $11.1M | Buy |
|
|||||
|
2019
Q4 | $12.7M | Sell |
|
|||||
|
2019
Q3 | $12.1M | Hold |
|
|||||
|
2019
Q2 | $11.3M | Sell |
|
|||||
|
2019
Q1 | $14.4M | Buy |
|
|||||
|
2018
Q4 | $9.24M | Buy |
|
|||||
|
2018
Q3 | $13.2M | Buy |
|
|||||
|
2018
Q2 | $7.84M | Sell |
|
|||||
|
2018
Q1 | $9.04M | Buy |
|
|||||
|
2017
Q4 | $1.55M | Buy |
|